Wes Streeting’s announcement of an inquiry into NHS ADHD, autism and mental health services has sparked widespread discussion. Whether these conditions are over-diagnosed or under-recognised, one thing is clear — diagnosis must be both accurate and accessible.
For many people, an ADHD diagnosis is not a label; it is the beginning of understanding themselves, accessing support, and improving long-term wellbeing.
However, long waiting times, inconsistent assessment pathways, and reliance on subjective tools mean too many individuals spend years without the clarity they need. Delayed diagnosis and limited access to treatment can have real consequences — including poorer mental health outcomes, greater risk of school or work difficulties, and higher rates of substance misuse.
That’s why conversations about diagnostic processes should focus on improvement, not restriction.
At Braingaze, we’re committed to supporting neurodevelopmental services through evidence-based innovation:
- BGaze Clinic brings greater objectivity to ADHD assessment using biomarkers and AI-driven analysis — helping clinicians make informed decisions backed by neuroscience.
- BGaze Focus provides an intervention to support individuals with ADHD and attentional difficulties by training neural pathways using the same biomarker.
Accurate and timely diagnosis prevents harm and allows patients to thrive — better tools empower clinicians to deliver both.